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Abstract : Early diagnosis and prompt treatment of tuberculosis is important in order to minimise complications and
sequale. It is important to select the proper regimen and ensure that hte patient is getting adeuqate number of
drugs for adequate duration. The principles of short course chemotherapy and the rationale behidn the currently
recommended regimens are outlined in this article. Standard (daily or intermittent) 6-month short course regimens
are sufficient to cure most forms of tuberculosis in children and only severe form slike miliary, meningitis and neuro-
tuberculosis require a longer duration of treatment. Worldwide, the DOTS strategy is now recommended in order to
ensure cure and cut down the transmission of disease in the community and wherever possible, should be employed
in the treatment of tuberculosis in children also.
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Thetherapyof tuberculosishasundergonemajorchanges
in the past 15-20 years. Upto the early 1980s, the
recommendedtreatmentdurationforadultsandchildren
was as long as 18 months. These standard regimens
wereassociatedwithpoorcomplianceandthereforehigh
failure and relapse rates. Though itwas known from the
1960s that supervised intermittent treatment was as
effective as daily treatment this mode of therapy was not
widely followed.With the introductionof rifampicinand
the re-discovery of pyrazinamide in the 1970s, short
course regimens evolvedwhich led to themodern era of
chemotherapy of tuberculosis. Initially, most trials were
conducted in adults and the results extrapolated to
children; however,most of these recommendationshave
now been validated by controlled trials in children.
MICROBIOLOGICBASIC FORTREATMENT
Types of Bacterioal Population
M. tuberculosis exists as distinct bacterial populations in
the host, eachwith different rates ofmetabolic activity and
replication.The tuberclebacillus canbekilledonlyduring
replicationandbeinganobligate aerobe, its activityvaries
with oxygen supply. Bacilli are present in extracellular
locations within cavitary walls (rapidly multiplying) and
also wihin the caseous material. In additionl, they are
present within macro-phages as they are able to resist
lysosomal killing. Cavitary lesions with high oxygen
tension lead to a very large bacterial population (107-109),
closed cas-eous lesions with neutral pH have moderate
numbersofbacilli (105-107) replicatingintermittentlywhile
the bacterial population in macrophages with acidic pH
(104-106) is small andmultiples very slowly.1,2.
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Presence of Natural Drug Resistant Mutants
Another important consideration is the occurrence of
natural drug-resistants in bacterial populations
ofM.Tuberculosis.3Themean frequencyof thesemutants
is 1 in 105 bacilli for streptomycin, 1 in 106 for isoniazid
and1in107 forrefampicin.Acavitywith109 bacilliwould
thereforehaveseveralhundreddrug- resistantmutuants
wheras lesions of primary tuberculosis or extra-
pulmonaryTBhave few, if any,mutants. The chance that
a mutant is naturally resistant to two drugs is very
small (1011 to1013). Ifpatientsare treatedwithasingledrug,
the drug resistant mutants will selectivelymultiply.
Size of the Bacillary Population
Adults with cavitary lesions housing large bacterial
populations, must be tratedwith at least 3 to 4 drugs to
prevent the multiplication of drug resistant mutants.
However,childrenwithprimarypulmonary tuberculosis
and patients with extra pulmonary tuberculosis have
smaller bacterial loads and can be treated with fewer
drugs (minimum2)withoutmuchriskofdrug- resistant
mutantsmultiplying.Patientswithinfection(positiveskin
test)butnodiseasehaveaverysmallbacterialpopulation
(103 to 104 organisms) and can bemanagedwith a single
drug.
Actions of Anti-Tuberculosis Drugs
Antituberculosis drugs work in 3 ways: bactericidal,
sterilizationandpreventionof resistance.Eachdrugacts
in a slightly different manner (Table 1). The large
population of actively replicating extracellular tubercle
bacilli (GroupA)arerapidlykilledbyisoniazid, rifampicin
and streptomycin. Rifampicin and isoniazid kill
organisms in closed caseous lesions while intracellular
organisms (Group C) are affected mainly by pyrazina-
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TABLE 1 : Bacillary Population andDrugActions
Bacillary Population Drug
mide. Thus a combination of isoniazid, rifampicin and
pyrazinamidewouldtakecareofbacilli indifferentstages
ofmatabolicactivity,producingsterilizationof the lesion.
Lag Phase
M.tuberculosisexhibitsa lagperiod ingrowth inresponse
to anti-TBdrugs.After exposure to thedrug, thegrowth
of the bacillus is inhibited for a variable period of time
ranging from 2 to 40 days (Table 2). This property
enables intermittent administrationofdrugswithgood
therapeutic effect.However, it is important that thepeak
drug concentration achieved should be above theMIC.
Acontrolled clinical trial undertaken at the Tubeculosis
ResearchCentre (TRC)had shown that a twice -weekly
intermittent regimenof streptomycinand isoniazidwas
as effective as adailyoral regimenofPASand isoniazid,
both regimens being given for 12 months4. Various
Group - A
Metabolically active, continuosly
growing bacilli in neutral pH
Group -B
Dormantmost of the time, occasionally
growing for short periods
Group -C
Intracellular bacilli in acidic pH
Group -D
Dormant bacilli
Streptomycin
Isoniazid
Rifampicin
Rifampicin
Pyrazinamide
Nodrug
attempts to reduce the frequency toonce aweekhavenot
beensuccessful,hence intermittentchemotherapyshould
be given at least twice a week.
PRINCIPLES OF SHORT - COURSE
CHEMOTHERAPY
Thebilogic characteristics of tuberclebacilli listedabove
determine the principles of short course treatment for
tuberculosis.
1. A combinationof at least 3 to 4drugs shouldbeused
inthe initial intensive phase (2 months). The drugs
are isoniazid, rifampicin, pyrazinamide and either
streptomycin or ethambutol. This combination
ensures rapid killing of all populations of bacilli.
2. Drugs can be given either daily or intermittently
(twice or thrice weekly)
3. Theminimumdurationoftreatment is6monthswhen
TABLE 2 : Lag inGrowth ofM. tuberculosisAfter Temporary Exposure toDrugs.
Drug Concentration Lag (days) after exposure for
mg/1 6h 24h
Isoniazid 1 0 6 - 10
Streptomycin 5 8 - 10 8 - 10
Rifamicin 0.2 2 - 3 2 - 3
Pyrazinamide 50 5 - 40* 40
Ethambutol 10 0 4 - 5
Ethionamide 5 0 10
Thoacetazone 10 0 0
* Depending on the pH of themedium (6.2 - 5.6)
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rifampicin is used throughout and pyrazinamide is
used in the intial intensive phase. If only 2 drugs are
used, the duration of treatment has to be at least 9
months.
4. The drugs should preferably be given together and
administered as a single dose.
The advantages of SSC are:
i) It has a faster and more powerful bactericidal and
sterilizing action so that even if the patient defaults
after the first fewmonths of therapy, he is likely to be
cured.
ii) The patient is exposed to potentially toxic drugs for
shorter periods of time.
iii) The regimens are less expensive and more cost-
effective than traditional therapy.
iv)More time and resources can be allotted to ensuring
compliance.
Various studies in adults have shown that with a
combinationof rifampicin, isoniazidandpyrazinamide
with either streptomycin or ethambutol, about 90% of
patientsbecomeculture-negativeby theendof2months
(bactericidal effect of the regimen)5. Continuing the
treatment with rifampicin and isoniazid for further 4
months results in almost 100% of patients with drug
sensitive organisms becoming culture-negative and
bacteriological relapse occuring in only about 5% of
patients (sterilizingeffect of the regimen)2.6. If the second
phase iswithout rifampicin, the total durationhas to be
at leasteightmonths.Chemotherapyoflessthan6months
duration is associated with higher relapse rates.
Theprinciplesofshortcoursechemotherapymay
becombinedwith intermittmentchemotherapytodevise
highly effective regimens, which can be given under
supervision to avoid non-compliance. TheWHO is now
implementing the DOTS strategy (directly observed
treatment, short-course) in places with a high incidence
of tuberculosis. By ensuring cure, this strategy aims at
reducingthenumberof infectiouscases inthecommunity
and also preventing the emergence of drug resistance.
CHEMOTHERAPY
Theprinciplesofchemotherapyinchildrenandadults
are the same. However, the exact regimens used vary
depending onthe nature and severity of illness e.g.
tuberculous meningitis, bone and joint TB and certain
other severe forms need longer regimens. Most other
formsof extrapulmonaryTB likeabdominalTB,pleural
effusionandTB lymphadenitis canbeeffectively treated
using the standard 6 month regimens.
Thedrugabbreviationsareas follows:E-Etham-
butol, H-Isoniazid, R-Rifampicin, S-Streptomycin and Z-
Pyrazinamide.Thenumberinfrontoftheregimendenotes
the number of months and the subscript after the drugs
denote the frequency of administration (number of doses
per week).
TRC Trial of short Course Chemotherapy for
Pulmonary Tuberculosis.
This trial was undertaken to study the efficacy of a 6-
month intermittent regimen and compare it with a
standard(daily)9-monthregimen7.Atotalof137children
with pulmonary tuberculosis were treated with one of
the following 2 regimens:
i) Isoniazid and rifampicin administered daily for 9
months (9HR) - thedrugswere collectedonce aweek
and administered at home.
ii) Isoniazid, rifampicinandpyrazinamide thriceaweek
for the first two months followed by isoniazid and
rifampicintwiceaweekforthenext4months(2HRZ3/
4HR2) - all doses were fully supervised.
The diagnosis was based on radiological abnormality
whichwas classified as most probable (categoryA) and
probable (B).Sixtyeight (50%)patientshadparenchymal
lesions alone, 34 (25%) had adenitis alone (mediastinal,
hilar or both), 10 (7%) had cavitary lesions while the
remaining25(18%)hadcombinedlesions.Onadmission,
56% of the patients were less than five years old,
tuberculin testwithITUwaspositive in72%andahistory
of contact with a known case of TB was pesent in 78%.
Culture was positive for M. tuberculosis in a total of 44
(32%)patients.Of the 137patients, 68 received regimen I
and 69 regimen II.
The response to treatmentwas similarwith both the
regimens. Of the 137 patiens, 3 (2%) died, in 74 (54%)
theradiological lesionsdisappearedcompletelywhile 60
(44%)had residual lesions.Of thepatientswith residual
lesions, 9 (5 in regimen I and 4 in regimenII) continued
treatment for a furtherperiodof 3monthsbecause their
lesions showed minimal or no clearance. The residual
lesions in the other patients continued to improve even
after stopping treatment.
The main conclusions from this trial were:
a) Shortcoursechemotherapy(SCC)withanintermittent
6monthregimenwasfoundtobeaseffectiveasadaily
9month regimen inpediatric pulmonaryTB.
b) The mortality and drop out rates were very low.
c) The adverse reactions were negligible.
d) Radiological clearance at the end of therapy was
similar in both nodal and parenchymal lesions and
the improvement continued even after stopping the
treatment.
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There have been a few other studies of SCC in
children (Table3)12.Theresultsofmosthavebeensimilar
with high sucess rates, low adverse reactions and low
relapse rates. Therefore, the present recommendation
wouldbetotreatpulmonarytuberculosis inchildrenwith
a 6 month regimen consisting of at least isoniazid,
rifampicin and pyrazinamide in the initial (2 months)
intensive phase followed by 2 drugs for the remaining 4
months (2HRZ/4HRor2HRZ3/4HR3).Thedrugsmay
begivendailyor intermittently.However, in thepresence
of extensive parenchymal lesions or a child who is
seriously ill, it would be advisable to add a 4th drug
(ethambutolor streptomycin) to the intensivephase.The
ATS and CDC both recommend the addition of a 4th
drug (usaually ethambutol) to the intensive phase. The
ATSandCDCbothrecommendtheadditionofa4thdrug
(usually ethambutol) to the initial regimen if the risk of
drug resistance is high (greater than 4% incidence in the
community or the patient already has been treated for
tuberculosis)13. Inmost parts of India, the prevalence of
INH-resistance is about 20%, hence the use of 4 drugs
initially is probably justified14. Childrenwithminimal/
TABLE 3 : Results of Six - Month Treatment Regimens for Tuberculosis
Author, Country Diagnostic No. of Regimen Results
and Year Criteria Children
Ibanez and Smear and 15 2 SHRZ /4SHZ2 1 failure,
Ross8 culture 0 relapses
Chile, 1980 Positive pulm.
TB 39 2 HRZ / 4HZ2 0 failures
Culture positive 0 relapses
pulm. TB
Varudkar9 Clinical and 100 2 HRE /4 HE 0 failures
India, 1985 bacteriological 40 2 HZE/ 4 HE 0 relapses
45 6 HRE3
Biddulph10 Clinical and 639 2 SHRZ /4 HR2 12 (2%) died
New Guinea, 1990 bacteriological 7 (1%) relapses
5/ 7 relapses in
poorly complaint
patients.
Kumar et al11 Clinical and 37 2 HRZ2 /4 HR2 2 deaths not related
India, 1990 bacteriological 39 2 HRZ/ 4 HR2 to TB
45 0 relapses
Ramachandran Clinical, 68 9 HR 3(2%) died
et al radiological and 0 failures
India, 1998 bacteriological 69 2 HRZ3/ 4 HR2 3 relapses
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mild lesionsor lymphnodedisease alone, however, can
still bemanaged satisfactorilywith the 3drug regimen.
The Indian Academy of Pediatrics Working Group
arrived at a consensus on the treatment of childhood
tuberculosis at a meeting in January 199715. In their
recommendations, tuberculosis is classified into five
groups based on clinical types and severity. Of these,
preventive therapy forms the first gropu and clinical
disease is classified into the other 4 groups. The main
recommendations are outlined below:
1. Primary Complex, pleural effusion and isolated
lymphadenitismaybe treatedwith 2HRZ/4HR.
2. Progressive pulmonary disease and multiple
lymphadenitisshouldbetreatedwith2HRZE/4HR.
3. Severe forms of tuberculosis like miliary /
disseminated disease, osteoarticular abdominal,
pericardial or genitourinary diseasewith 2HRZE/ 7
HRE.
4. Neuro tuberculosiswith 2HRZE/10HRE.
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Table 4 lists the commonlyuseddrugsalongwith their
dosages,mechanismsofactionandadverse reactions.
ExtraPulmonaryTuberculosis
Controlled trials for various forms of extra pulmonary
tuberculosis in childrenare rare. Several of the 6-month
3-drug trials inchildren includedextrapulmonarycases.
Most non-life threatening formsof extra pulmonaryTB
inchildrenrespondwell toa9monthcourseof isoniazid
andrifampicinortoa6monthregimenincludingisoniazid,
rifampicin and pyrazinamide. A trial conducted by TRC
on lymph node TB in children showed that a short
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TABLE 4 : Commonly used Drugs for the Treatment of Tuberculosis
Drug Dosage
forms
Isoniazid
Rifampicin
Pyrazinamide
Ethambutol
Streptomycin
(i.m. admin.)
course fully supervised intermittent regimen (2SHRZ3/
4SH2)was successful
16.Clinical responsewas favourable
in most patients at the end of treatment and only 3%
required re0treatment for TB, after 36 months of follow
up.However, 30%ofpatienshadresidualnodes>10mm
diameter at the end of treatment which regressed
subsequentlywithout further treatment.Appearance of
new nodes, sinuses and abscesses and enlargement of
existing nodeswas observed both during treatment and
follow up.
Tuberculous meningitis (TBM) usually is not
includedintrialsofextrapulmonarytuberculosisbecause
Dose
(mg/kg)
Daily Thrice
Weekly
Mechanism of action Adverse reactions
Tablets
100 mg
300 mg
Syrup
100 mg / 5ml
Capsules
150 mg
300 mg
450 mg
600 mg
Syrup
100 mg / 5ml
Tablets
250 mg
500 mg
750 mg
1 g
300 mg disp
tap
Syrup
250 mg / 5ml
Tablets
200 mg
400 mg
600 mg
800 mg
1 g
Vials
0.75 g
1.0 g
5 10-15
10 10
20 - 30 35 - 50
15 - 20 25 - 35
20 20
Bactericidal, exact
mechanism not known.
Damages cell membrane.
Inhibits DNAdependant
RNA polymerase
Bactericidal
Bactericidal, exact
mechanism not known.
Sterilising effect. Little
effect when used beyond
2 months
Bacteriostatic. Actsmainly
against rapidlymultiplying
organisms
Bactericidal in higher
concentrations. In
meningitis, therapeutic
concentrations are
achieved in CSF.
GI, psychosis,
allergic reaction,
peripheral
neuropathy,
hepatitis, lupus
Hepatotoxicity, GI
allergic reaction,
renal impairment
Intermittment-flu
syndrome, purpura.
Arthralgia,
hyperuricemia,
gastrointestinal,
allergic reaction,
hepatotoxicity.
Optic neuritis,
colour blindness,
gastro intestinal,
allergic reaction
Hypersensitivity
reactions, vestibular
dyfunction, optic
neuritis, deafness,
renal damage.
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of its seriousnatureand lowincidence.Atrial conducted
by TRC on 180 patients with TBM tried 3 different
regimens, each for 12 months17.
i) 2SHR/4S2EH/6EH
ii) 2SHRZ / 10EH
iii) 2R2SHZ / 10EH
The response to treatment was similar with the 3
regimens.Therewasaclearassociationbetweenthestage
onadmissionandtuberculosisdeaths, themortalitybeing
9% for stage I patients, 25% for stage II and 73% for stage
III.
A study from Thailand showed that a 6-month
regimen including pyrazinamide (6SHRZ) for serious
TBM led to fewer deaths and better outcomes than did
longer regimens that did not contain pyrazinamide18.
Donald et al treated 95 children with tuberculous
meningitis with an intensive 6-month short course
regimenconsistingof isoniazid rifampicin, ethionamide
(20mg/kg)andpyrazinamide(40mg/kg).Themortality
was 26% in stage III and6% in stage II disease. Eighteen
children (20%) developed a mildly elevated serum
bilirubinconcentrationduringthefirstmonthof treatment
and in 5 thedrugshad tobe temporarily subtitutedwith
streptomycin andethambutol19.Currently,most centres
treat childrenwithTBM, initiallywith4drugs (isoniazid,
rifampicin, pyrazinamide and ethambutol or
streptomycin).Thepyrazinamideand4thdrugarestopped
after2monthsandisoniazidandrifampicinare continued
for a total of 9 to 12months. Intensive initial therapymay
beimportanttominimizeneurologicsequealae.However,
themostimportantfactorthatdeterminesoutcomeinTBM
is the stage of disease at which the patient is brought to
hospital.
Drug - Resistant Tuberculosis in Children
Theincidenceofdrug-resistant tuberculosis is increasing
in Indiamainlydue topoor treatment adherenceby the
patientandpoormanagementbyphysicians.Initialdrug
resistance to isoniazid is reported to be in the rangeof 20
to 25% and for rifampicin, range is 2 - 3%14. These rates
aremuchhigherinpatientswhohavetakenprior, irregular
treatment. Patterns of drug resistance in children
tend to mirror those found in adult patients in the
population.As it isdifficult tocultureM.tuberculosis from
childrenwithTBthecluetodrugresistanceusuallycomes
fromtheadultcontact.Drugresistant tuberculosisshould
be suspected inthe following circumstances :
i) The child is in contact with a known case of drug-
resistant tuberculosis.
ii) Childs adult contact has been on chronic irregular
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treatment and continues to be sputum positive.
iii) Adult contact died after taking irregular treatment.
iv) Child showed some intial improvement to anti-
tuberculosis treatment but then deteriorated (clinically
and radiologically)
The only definitive way of diagnosing drug
resistance is by isolating the strain and assessing its
susceptibility patternwhich takesmonths. New rapid
culture and susceptibility tests namely BACTEC,
mycobacterial growth indicator tuber (MGIT) and
luciferasereporterassayhavebeendevelopedwhichoffer
the possibility of early sensitivity results. In addition,
advancedmolecularbiologic techniques likepolymerase
chain reaction, DNA fingerprinting and SSCP (single)
strand conformationpolymorphism) are rapid andhelp
by identifying themutations that cause drug resistance.
However, these are not available for routine use.
Therapy fordrug-resistant tuberculosis is successful
when at least two bactericidal drugs to which
the infecting strain ofM. tuberculosis is susceptible are
given. Exact treatment regimens can be tailored to the
specificpatternofdrugresistance, ifknown. Ifnot, at least
3 drugs towhich the patient has not been exposed earlier
shouldbegiven20.Resistance to isoniazidor streptomycin
alone can usually be managed with any of the standard
4-drug regimens with good results. However, when
resistance to both isoniazid and rifampicin is present
(MDRTB),managementismorecomplicatedandrequires
theuseofsecondlinedrugs.Durationoftherapyisusually
extended to 9-12 months if either isoniazid or rifampicin
can be used and to at least 18-24 months if resistance to
both drugs is present. Occassionally, surgical resection of
a diseased lung or lobe is required.
Corticosteroids
Corticosteroidsaremostbeneficial insituationswhere the
host inflammatory reaction contributes to tissue damage
or impairs function. They should never be used except
under cover of effective anti-tuberculosis drugs. Steroids
are a useful addition to anti-tuberculosis drugs in the
followingsituations21.
1. In patients with tuberculous meningitis and raised
intracranial pressure. Theyhelp to reducevasculitis,
inflammation and intracranial pressure and reduce
long-termneurologic sequelae22.
2. In patients with pericardial effusion in whom
tamponade is imminent.
3. In patients with pleural effusion in whom there is
mediastinal shift with acute respiratory
embrassment.
4. In patients with miliary tuberculosis if the
inflammatory reaction is severe enough to produce
cyanosis.
5. Inpatientswith enlargedmediastinal nodes causing
respiratory difficulty or a severe collapse-
consolidation.
The dosage of steroids should be in the anti-
inflammatoryrange, i.e.prednisolone1-2mg/kg/dayfor
4 to 6weekswith gradualwithdrawal.
Conclusion
Short course chemotherapy of tuberculosis is reliable,
efficaciousaswellascost-effective23,24.Whereverfeasible,
chemotherapy should be given under direct supervision
(DOTS) as thiswill ensure cure in themajority of cases25.
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